Rafael Holdings, Inc. Class B (RFL): Price and Financial Metrics
GET POWR RATINGS... FREE!
RFL POWR Grades
- Momentum is the dimension where RFL ranks best; there it ranks ahead of 66.24% of US stocks.
- The strongest trend for RFL is in Stability, which has been heading down over the past 31 weeks.
- RFL ranks lowest in Growth; there it ranks in the 0th percentile.
RFL Stock Summary
- For RFL, its debt to operating expenses ratio is greater than that reported by just 0.5% of US equities we're observing.
- RFL's price/sales ratio is 173.87; that's higher than the P/S ratio of 97.52% of US stocks.
- Over the past twelve months, RFL has reported earnings growth of 234.2%, putting it ahead of 92.2% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Rafael Holdings Inc are TACT, DRTT, XONE, BLNK, and DZSI.
- Visit RFL's SEC page to see the company's official filings. To visit the company's web site, go to www.rafaelholdings.com.
RFL Stock Price Chart Interactive Chart >
RFL Price/Volume Stats
|Current price||$43.70||52-week high||$53.57|
|Prev. close||$41.68||52-week low||$12.08|
|Day high||$46.27||Avg. volume||63,870|
|50-day MA||$43.27||Dividend yield||N/A|
|200-day MA||$29.35||Market Cap||774.41M|
Rafael Holdings, Inc. Class B (RFL) Company Bio
Rafael Holdings, Inc., through its subsidiary, manufactures metabolic oncology drugs to treat cancer. The company also owns and operates real estate properties. The company was incorporated in 2017 and is based in Newark, New Jersey. Rafael Holdings, Inc. operates as a subsidiary of IDT Corporation
RFL Latest News Stream
|Loading, please wait...|
RFL Latest Social Stream
View Full RFL Social Stream
Latest RFL News From Around the Web
Below are the latest news stories about Rafael Holdings Inc that investors may wish to consider to help them evaluate RFL as an investment opportunity.
If you want to know who really controls Rafael Holdings, Inc. ( NYSE:RFL ), then you'll have to look at the makeup of...
Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program
CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer. “We are incredibly proud to have data to share in two hard-to-treat cancers; as challenging as the past year has been to ensure that we continue to move the needle, we have been able to make significant progress,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “The data continues to show us hope for the future, with our continue...
Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Company meets enrollment milestones to support research and development of a new and novel treatment for hard-to-treat cancerCRANBURY, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has crossed the enrollment of 150 patients in its Phase 3 clinical trial for patients with relapsed or refractory acute myeloid leukemia (AML) (ARMADA 2000). The multicenter, open-label, randomized pivotal trial is assessing the efficacy and safety of Rafael’s lead compound CPI-613® (devimistat) in combination with high dose cytarabine and mitoxantrone (CHAM) compared to high dose cytarabine and mitoxantrone (HAM) therapy in older patients. The announcement comes ...
The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...
President and CEO Sanjeev Luther and Co-Chief Medical Officer Tim Pardee, M.D., Ph.D., will discuss clinical trial launches, FDA-granted Fast Track designations and other recent accomplishments on Wednesday, Jan. 20CRANBURY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, President and CEO, and Timothy S. Pardee, M.D., Ph.D., Co-Chief Medical Officer of the Company, will present at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, Jan. 20. “As we kick off 2021, we are excited to present the progress that Rafael Pharmaceuticals has made throughout the past year,” said Sanjeev Luther, President and CEO of Raf...
RFL Price Returns